I'm simply mentioning those because they are the journals associated with any potential abstracts from companies. I know you are looking at it through a different lens, aka: still blinded publication (which would not likely be an abstract), but I thought I'd keep things updated as well on any possible/potential upcoming unblinded abstract -- should one be (or been) submitted.
First you defend the paper publicly, then you publish it. Now that's peer review. Following the proven path is the safest bet, whether that be median PFS, median OS, or platform followed by paper.